Home Cart Sign in  
Chemical Structure| 888216-25-9 Chemical Structure| 888216-25-9

Structure of Ganetespib
CAS No.: 888216-25-9

Chemical Structure| 888216-25-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ganetespib (STA-9090) is an HSP90 inhibitor that exhibits potent cytotoxicity in various hematological and solid tumor cell lines. It also has antiangiogenic effects in colorectal cancer through inhibition of HIF-1α and STAT3.

Synonyms: STA-9090

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ganetespib

CAS No. :888216-25-9
Formula : C20H20N4O3
M.W : 364.40
SMILES Code : O=C1N(C2=CC3=C(N(C)C=C3)C=C2)C(C4=CC(C(C)C)=C(O)C=C4O)=NN1
Synonyms :
STA-9090
MDL No. :MFCD22420818
InChI Key :RVAQIUULWULRNW-UHFFFAOYSA-N
Pubchem ID :135564985

Safety of Ganetespib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Ganetespib

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
H460 cells 30 nM 5 hours Ganetespib significantly reduced radiation clonogenic survival in H460 cells and enhanced radiation-induced G2/M arrest. PMC5135582
A549 cells 30 nM 5 hours Ganetespib significantly reduced radiation clonogenic survival in A549 cells and enhanced radiation-induced G2/M arrest. PMC5135582
H1299 cells 30 nM 5 hours Ganetespib significantly reduced radiation clonogenic survival in H1299 cells and enhanced radiation-induced G2/M arrest. PMC5135582
H1650 cells 30 nM 5 hours Ganetespib significantly reduced radiation clonogenic survival in H1650 cells and enhanced radiation-induced G2/M arrest. PMC5135582

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NCr nu/nu mice H460 and A549 xenograft models Intravenous injection 100 mg/kg Once weekly for two weeks Ganetespib significantly enhanced the anti-tumor effect of CRT in the H460 xenograft model, but accelerated tumor progression in the A549 model. PMC5135582

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01200238 Ocular Melanoma PHASE2 COMPLETED 2016-11-11 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02115, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States Less <<
NCT01562015 Non Small Cell Lung Cancer PHASE2 COMPLETED 2025-11-14 Synta Pharmaceuticals Investig... More >>ative Site, Tampa, Florida, 33612, United States|Synta Pharmaceuticals Investigative Site, Cleveland, Ohio, 44195, United States|Synta Pharmaceuticals Investigative Site, Hamilton, Ontario, ON L8V 5C2, Canada|Synta Pharmaceuticals Investigative Site, Ottawa, Ontario, K1H 8L6, Canada|Synta Pharmaceuticals Investigative Site, Toronto, Ontario, M5G 2M9, Canada Less <<
NCT01551693 Melanoma PHASE2 TERMINATED 2025-09-12 Dana-Farber Cancer Institute, ... More >>Boston, Massachusetts, 02215, United States Less <<
NCT01665937 Hepatocellular Carcinoma PHASE1 COMPLETED 2025-03-14 Beth Israel Deaconess Medical ... More >>Center, Boston, Massachusetts, 02115, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Massachusetts General Hospital, Boston, Massachusetts, 02115, United States Less <<
NCT01590160 Lung Cancer - Malignant Pleura... More >>l Mesothelioma Less << PHASE1|PHASE2 COMPLETED 2019-11-05 UCL Cancer Trials Centre, Lond... More >>on, W1T 4TJ, United Kingdom Less <<
NCT00687934 Solid Tumors PHASE1 COMPLETED 2025-10-11 Premiere Oncology, Santa Monic... More >>a, California, 90404-2111, United States|US Oncology Dayton Oncology and Hematology, P.A, Kettering, Ohio, 45409, United States Less <<
NCT01167114 Esophagogastric Cancer PHASE2 COMPLETED 2025-04-17 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02115, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States Less <<
NCT01273896 Breast Cancer PHASE2 COMPLETED 2025-09-13 Memorial Sloan-Kettering at Ba... More >>sking Ridge, Basking Ridge, New Jersey, 07920, United States|Memorial Sloan-Kettering Cancer Center at Commack, Commack, New York, 11725, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Memorial Sloan-Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, 11570, United States|Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow, New York, 10591, United States Less <<
NCT01111838 Colon Cancer|Rectal Cancer PHASE2 COMPLETED 2025-07-12 Memorial Sloan-Kettering Cance... More >>r Center, New York, New York, 10065, United States Less <<
NCT01173523 Small Cell Lung Cancer PHASE2 COMPLETED 2016-11-04 Massacusetts General Hospital,... More >> Boston, Massachusetts, 02114, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02115, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States Less <<
NCT01039519 Gastrointestinal Stromal Tumor PHASE2 COMPLETED 2025-12-11 UCLA Medical Center, Los Angel... More >>es, California, 90095, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Oregon Health and Science University-Knight Cancer Institute, Portland, Oregon, 97239, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111-2497, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.74mL

0.55mL

0.27mL

13.72mL

2.74mL

1.37mL

27.44mL

5.49mL

2.74mL

References

 

Historical Records

Categories